Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the pharmacokinetics of moxifloxacin in children to
see what the best dose should be for children in the future. Pharmacokinetics is to see how
the body absorbs, distributes, breaks down and gets rid of the study drug. The
pharmacokinetics of certain drugs may be altered in children due to developmental differences
in various organ functions responsible for drug elimination, as well as in general
distribution characteristics. The safety of moxifloxacin in children with infections will
also be looked at. Results from this study will be used to guide dosing strategies of the
larger clinical trial planned for children
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination